Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kolofort in Functional Dyspepsia
NCT03119766Phase 4Completed
- Sponsor
- Materia Medica Holding
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in functional dyspepsia (FD) comparing Kolofort with Placebo (2 arms). Primary endpoint: Changes in Severity of Functional Dyspepsia Symptoms at 8 weeks. Started Jun 2017; status: completed.
02
Drugs
Kolofort
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT03119766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119766.